大幅反発。11日の取引終了後、生成AI関連開発のエンジニア集団であるLangCoreの株式を取得し連結子会社化することを発表し、好材料視されている。取得価額は4億円。LangCoreの子会社化により、同社における生成AI技術力の更なる向上と開発案件の拡大や生成AI SaaSの新規開発などのシナジーを早期に創出し、両社の短期的な収益向上が実現されるとともに、中長期的な事業拡大も見込まれるとしている。＜7373＞ Aidoma HD 1614 +12
fight. Financial results for the fiscal year ended 24/8 were announced after the end of trading on the 11th, and there was a standoff even after the rise began. Sales were strong at 10.618 billion yen (up 17.2% from the previous fiscal year), operating profit was 2.468 billion yen (up 11.7% from the same period), and ordinary profit was 2.468 billion yen (up 11.0% from the same period). Centering on sales platform services, which are our main services, we actively promote the development of work innovation businesses, and receive orders from many small to medium enterprises that require online sales methods in an environment where telecommuting has become established.
＜5591＞ AVILEN 1040 +97
Massive backlash. After the transaction ended on the 11th, it was announced that the shares of Langcore, which is an engineer group for generative AI related development, will be acquired and made into a consolidated subsidiary, and it is viewed as good news. The acquisition price is 0.4 billion yen. By making LangCore a subsidiary, synergy such as further improvement in the company's generative AI technology capabilities and expansion of development projects and new development of generative AI SaaS will be created at an early stage, and short-term profit improvements for both companies will be realized, and medium- to long-term business expansion is also expected.
＜4570＞ Institute for Immunobiology 505 +80
The stop is high. After the transaction ended on the 11th, it was announced that they had obtained a patent in Japan relating to “anti-HIV antibodies and their manufacturing methods,” and purchases that were well received by this have become dominant. This patent is granted to a new drug candidate substance itself, and even if the manufacturing method is different, it is called a “substance patent” where rights extend to all of them if the manufactured substances are the same, and the scope of rights is the broadest among pharmaceutical patents. Patents have already been assessed in China, Hong Kong, and Taiwan, and it is said that the examination of the same patent applied for in Europe and the United States is progressing smoothly.
＜189A＞ D&M Company 869 -16
Decline. Results for the 1st quarter of the fiscal year ending 25/5 were announced after the transaction ended on the 11th. Net sales remained steady at 0.441 billion yen (up 44.1% from the same period last year) and ordinary profit of 0.086 billion yen (up 18.1% from the same period). The number of F&I service debt purchasing companies steadily increased, and sales of large medical related devices for C&Br services contributed. Also, for HR&OS services, preparations are underway to expand the provision of outsourcing services, and it is said that sales are expected to increase from the 2nd quarter onwards. However, the positive impact on stock prices has been limited.
＜4881＞ FAN PEP 131 +1
backlash. It was announced that joint research on novel adjuvants for antibody-inducing peptides has begun with Shionogi Pharmaceutical. The purpose of this joint research is to search for novel adjuvants of antibody-induced peptides with excellent efficacy, safety, and convenience by utilizing Shionogi Pharmaceutical's vaccine development and adjuvant technology know-how, and mainly Shionogi Pharmaceutical will examine formulations of new adjuvants, and the company plans to conduct drug efficacy evaluations and safety evaluations in animal tests. Expenses related to the work in charge of the joint research will be borne, but it is said that there is no change in the research and development cost forecast value for the fiscal year ending 24/12.
＜3991＞ Wanted Tree 1192 +57
skyrocketing. Consolidated financial results for the fiscal year ended 24/8 were announced and viewed as good news. Operating revenue was 4.722 billion yen (down 0.5% from the previous fiscal year), but operating profit was 1.594 billion yen (up 0.3% from the same period), and ordinary profit was 1.579 billion yen (up 1.0% from the same period). In addition to continuing development and improvement of “Wantedly Visit,” which is the main product, we are proceeding with the provision of an “Engagement Suite,” and as of the end of 24/8, the number of registered enterprise users was 0.042 million companies and the number of registered individual users was 4.09 million, and sales are expected to increase by about 5% in the 25/8 fiscal year.
